Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions.

ABSTRACT:

Purpose of review

The purpose of this review is to summarize the status and utilization of chimeric antigen receptor T-cell (CAR-T) therapy based on the most recent clinical trials in patients with leukemia and lymphoma. Additionally, this review will highlight limitations in current strategies, discuss efforts in toxicity mitigation, and outline future directions for investigation.

Recent findings

CD19 targeted CAR-T-cell therapy (CD19-CAR) is highly effective in patients with relapsed/refractory (r/r) B-cell hematologic malignancies. However, multiple challenges have arisen, particularly life-threatening adverse events, such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Despite these challenges, recent CD19-CAR trials, including t

SUBMITTER: Schroeder BA 

PROVIDER: S-EPMC9354650 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature